Skip to main content
ResearchTreatments

FDA Accelerates Approval of Lurbinectedin in Metastatic SCLC

By September 18, 2020March 2nd, 2021No Comments

*June 2020*

The FDA had granted accelerated approval to the anti-cancer agent lurbinectedin (Zepzelca) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) whose disease has progressed on or after platinum-based chemotherapy. The accelerated approval was granted in light of the positive overall response rate (ORR) and duration of response (DOR) observed with the drug, PharmaMar and Jazz Pharmaceuticals announced. Read more.